Photo of Philip J. Saylor, MD

Philip J. Saylor, MD


Accepting New Patients





Centers & Specialties

Cancer Center

Clinical Interests
  • Prostate cancer
  • Renal (kidney) cancer
  • Bladder cancer
  • Testicular, penile and genito-urinary cancers
  • Genitourinary (GU) cancer
Medical Education
  • MD, University of Pittsburgh School of Medicine
  • Residency, UCSD Medical Center
  • Fellowship, Dana Farber Cancer Institute
Board Certifications
  • Internal Medicine
  • Medical Oncology
  • Boston: Massachusetts General Hospital
Patient Gateway
Yes, learn more
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • Centene/Celticare
  • Cigna (PAL #'s)
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • Medicaid
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • Private Health Care Systems (PHCS)
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO
Patient Age Group

Edit Profile

Research & Publications


View my most recent publications at PubMed

Saylor P, Kaufman D, Michaelson D, Lee R, Smith M. Application of the WHO/FRAX fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. Journal of Urology. 2010 Jun; 183(6):2200-5.

Saylor P, Fogerty A. Prostate cancer associated hypercoagulability: do we need to worry about androgen deprivation? Lancet Oncology. 2010 May; 11(5):406-7.

Saylor P, Smith M. Adverse Effects of Androgen Deprivation Therapy: Defining the Problem and Promoting Health among Men with Prostate Cancer. Journal of the National Comprehensive Cancer Network. 2010 Feb; 8(2): 211-23.

Saylor P, Smith M. Review: Bone Health and Prostate Cancer. Prostate Cancer and Prostatic Diseases. 2009 Mar; 13(1):20-7.

Saylor P, Keating N, Smith M. Prostate Cancer Survivorship: Prevention and Treatment of the Adverse Effects of Androgen Deprivation Therapy. Journal of General Internal Medicine. 2009 Nov; 24(2): 389-94.

Saylor P, Smith M. Prostate Cancer: How can we improve the health of men who receive ADT? Nature Reviews Urology. 2009 Oct; 6(10): 529-31.

Saylor P, Michaelson M. New Treatments for Renal Cell Carcinoma: Targeted Therapies. Journal of the National Comprehensive Cancer Network. 2009; 7(6): 645-56.

Saylor P, Smith M. Metabolic complications of androgen deprivation therapy for prostate cancer. Journal of Urology. 2009 May; 181 (5): 1998-2006.

Saylor P, Reid T. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. Journal of Clinical Oncology. 2007 Aug 10; 25 (23): 3544-3546.

Edit Profile


55 Fruit Street
Boston MA, 02114-2696
Phone: 617-724-4000617-726-8689
Fax: 617-643-2690

Edit Profile

Back to Top